NCT01704261View on ClinicalTrials.gov

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

PHASE3CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

October 18, 2012

Primary Completion Date

December 23, 2014

Study Completion Date

December 23, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Omarigliptin

Omarigliptin 25 mg capsule administered orally once a week

DRUG

Matching placebo to Omarigliptin

Matching placebo to omarigliptin capsule administered orally once a week

DRUG

Glimepiride

Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.

DRUG

Metformin

Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01704261 - Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) | Biotech Hunter | Biotech Hunter